Franklin Biotechnology Discovery Adv
(FTDZX)
US Markets Closed
AdChoices
156.12
+2.76
+1.80%
:

Previous Close

153.36

Net Assets

139.04M

Yield

0.00%

Front load

None

Expenses

0.80%

Category

Health

Morningstar Risk

Above Average

Morningstar Rating ★★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • FTDZX

  • Category

    • 2013

    • 69.15%

    • -

    • 2012

    • 29.72%

    • -

    • 2011

    • 8.65%

    • -

    • 2010

    • 17.64%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 19.45%

      • 17.57%

      • 5.28%

      • Q2

      • 9.08%

      • 9.79%

      • 7.38%

      • Q3

      • 25.07%

      • 5.62%

      • -15.18%

      • Q4

      • 3.80%

      • -4.85%

      • 13.31%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Gilead Sciences Inc

        • 8.82

        • 1,543,800

        • -372,000

        • Biogen Idec Inc

        • 7.49

        • 344,461

        • -8,800

        • Celgene Corp

        • 7.20

        • 1,215,400

        • 733,400

        • Amgen Inc

        • 4.95

        • 607,000

        • -67,900

        • Medivation Inc

        • 4.72

        • 887,954

        • -107,500

        • Regeneron Pharmaceuticals Inc

        • 4.01

        • 205,809

        • -45,200

        • Illumina Inc

        • 3.30

        • 267,900

        • -57,900

        • Incyte Corp Ltd

        • 3.03

        • 779,100

        • 0

        • Alexion Pharmaceuticals Inc

        • 2.73

        • 253,700

        • -34,700

        • Vertex Pharmaceuticals Inc

        • 2.60

        • 398,800

        • -70,800

        • Name

        • Rating

        • YTD Return %

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 15.57

          • VALIC Company I Health Sciences

          • ★★★★★
          • 16.58

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 15.85

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 16.85

          • Franklin Biotechnology Discovery A LW

          • ★★★★
          • 17.52

          • Fidelity Advisor® Health Care A LW

          • ★★★★
          • 18.09

          • Janus Global Life Sciences D

          • ★★★★
          • 17.90

          • Fidelity Advisor® Biotechnology T

          • ★★★★
          • 16.71

          • Prudential Jennison Health Sciences C

          • ★★★★
          • 14.89

          • Fidelity® Select Pharmaceuticals Port

          • ★★★★
          • 13.87

          • Name

          • FTDZX

          • Category

            • Expense Ratio

            • 0.80%

            • 1.45%

            • Net Assets

            • 139.04M

            • 711.24M

            • Dividend Yield

            • 0.16%

            • 0.61

            • Price/Book

            • 6.41

            • 4.82

            • Price/Sales

            • 9.60

            • 3.25

            • Price/Cash Flow

            • 21.18

            • 19.29

            Profile

            Name of Issuer

            Franklin Templeton Investments

            Fund Style

            Open

            Fund Manager

            Jerel Banks

            Investment Style

            Medium Growth

            The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.

            Purchase Information

            Initial Purchase 1,000,000
            Initial Purchase: IRA NA
            Initial Purchase: AIP NA
            Front load None
            Back Load None

            Inception

            9/1/2009